Latest news with #ConcordBiotech
Business Standard
13 hours ago
- Business
- Business Standard
Concord Biotech consolidated net profit declines 26.06% in the June 2025 quarter
Sales decline 5.47% to Rs 203.99 crore Net profit of Concord Biotech declined 26.06% to Rs 44.06 crore in the quarter ended June 2025 as against Rs 59.59 crore during the previous quarter ended June 2024. Sales declined 5.47% to Rs 203.99 crore in the quarter ended June 2025 as against Rs 215.80 crore during the previous quarter ended June 2024. Particulars Quarter Ended Jun. 2025 Jun. 2024 % Var. Sales 203.99215.80 -5 OPM % 30.1037.66 - PBDT 76.5192.70 -17 PBT 58.7379.52 -26 NP 44.0659.59 -26
Business Standard
14 hours ago
- Business
- Business Standard
Concord Biotech standalone net profit declines 26.91% in the June 2025 quarter
Sales decline 5.47% to Rs 203.99 crore Net profit of Concord Biotech declined 26.91% to Rs 42.57 crore in the quarter ended June 2025 as against Rs 58.24 crore during the previous quarter ended June 2024. Sales declined 5.47% to Rs 203.99 crore in the quarter ended June 2025 as against Rs 215.80 crore during the previous quarter ended June 2024. Particulars Quarter Ended Jun. 2025 Jun. 2024 % Var. Sales 203.99215.80 -5 OPM % 30.1037.66 - PBDT 75.0391.34 -18 PBT 57.2578.16 -27 NP 42.5758.24 -27
Business Upturn
26-07-2025
- Business
- Business Upturn
Concord Biotech successfully completes Russian GMP inspection at Dholka API facility
Concord Biotech is pleased to announce the successful completion of the Russian GMP (Good Manufacturing Practice) inspection at its Active Pharmaceutical Ingredient (API) manufacturing facility located in Dholka, Gujarat. The inspection was conducted from July 22, 2025, to July 25, 2025. In the exchagne filings, the company shared, 'We are pleased to announce the successful completion of the Russian GMP (Good Manufacturing Practice) inspection at our Active Pharmaceutical Ingredient (API) manufacturing facility located in Dholka, Gujarat. The inspection was conducted from July 22' 2025 to July 25' 2025.' This achievement underscores the company's commitment to upholding the highest standards of quality, safety, and regulatory compliance across all areas of its operations. It also reflects Concord Biotech's continued focus on meeting the rigorous requirements of global regulatory authorities. Ahmedabad Plane Crash Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
&w=3840&q=100)
Business Standard
25-07-2025
- Business
- Business Standard
Looking to buy in falling market? NMDC, Godrej Agro, 2 others may gain 19%
NMDC, Godrej Agrovet, Amara Raja Energy and Concord Biotech witnessed a breakout on the daily chart in recent trading sessions; here's a likely technical outlook for these 4 stocks. Rex Cano Mumbai Listen to This Article Benchmark indices - the BSE Sensex and the Nifty were seen trading with notable losses for the second straight trading session on Friday. The NSE Nifty declined 0.6 per cent or 240 points at 24,820 levels, while the BSE Sensex shed over 700 points or 0.9 per cent at 81,500 levels in intra-day deals. Meanwhile, here are 4 stocks that recently witnessed a technical breakout on the charts, with up to .. per cent upside potential in the coming period. On the charts, NMDC, Amara Raja Energy & Mobility, Godrej Agrovet and Concord Biotech witnessed a breakout above
&w=3840&q=100)
Business Standard
23-07-2025
- Business
- Business Standard
Concord Biotech rises 2% on incorporating its arm for marketing and sales
Concord Biotech shares rose 2.3 per cent, logging an intraday high at ₹1941.25 per share on the BSE. At 1:22 PM, Concord Biotech share price was trading 1.72 per cent higher at ₹1,930 per share on BSE. In comparison, the BSE Sensex rose 0.43 per cent to 82,544.23. The market capitalisation of the company stood at ₹20,190.93 crore. The 52-week high of the company stood at ₹2,658 per share, and the 52-week low was at ₹1,370.05. Why were Concord Biotech shares buzzing in trade? The buying on the counter came after the company incorporated its subsidiary Concord Lifegen, with an objective to carry out marketing, sales, and distribution of pharmaceutical products. The total cost of acquisition is worth ₹1,00,000. "We are pleased to announce incorporation of Concord's Wholly Owned subsidiary company, namely, 'Concord Lifegen Limited' with objective to carry out marketing, sales, and distribution of pharmaceutical products," the filing read. Its primary objectives include executing targeted sales strategies, ensuring regulatory compliance across domestic and international markets, handling logistics and customer support, and maintaining transparent reporting to the holding company, according to the filing. The authorised share capital (as on July 22, 2025) of Concord Lifegen is ₹1,00,000 divided into 10,000 equity shares of ₹10 each issued share capital (as on July 22, 2025). That apart, in Q4, the company's profit climbed 47.8 per cent year-on-year (Y-o-Y) to ₹140 crore in the March quarter of FY25, from ₹95 crore in the March quarter of FY24. Concord Biotech's revenue from operations surged 34.8 per cent Y-o-Y to ₹429.9 crore in Q4FY25, from ₹319 crore in the same quarter a year ago. About Concord Biotech Concord Biotech is a research-driven biopharmaceutical company specialising in the production of Active Pharmaceutical Ingredients (APIs) through fermentation and semi-synthetic processes, along with finished formulations. Initially a single-product entity, Concord has evolved into a comprehensive solutions provider, offering a broad range of products across various therapeutic segments. The company has established a global presence, distributing its products in over 70 countries, including key markets like the USA, Europe, Japan, and Latin America, while also maintaining a major footprint in India.
